Cheng CY, Hao WR, Liu JC, Cheng TH. Advancing oral cancer care: Insights from Tongluo Jiedu prescription. World J Clin Cases 2024; 12(35): 6764-6769 [DOI: 10.12998/wjcc.v12.i35.6764]
Corresponding Author of This Article
Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Chun-Yao Cheng, Department of Ophthalmology, Cathay General Hospital, Taipei 10633, Taiwan
Chun-Yao Cheng, Department of Medical Education, National Taiwan University Hospital, Taipei 100225, Taiwan
Wen-Rui Hao, Ju-Chi Liu, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei 23561, Taiwan
Wen-Rui Hao, Ju-Chi Liu, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan
Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan
Author contributions: Cheng CY and Hao WR conceptualized the editorial and provided critical insights into the relevance of the study; Liu JC contributed to the analysis and interpretation of the study’s findings; Cheng TH supervised the editorial process and provided overall guidance; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: All authors declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Received: May 15, 2024 Revised: September 2, 2024 Accepted: September 9, 2024 Published online: December 16, 2024 Processing time: 161 Days and 10.7 Hours
Abstract
This editorial highlights the study which investigated the potential of traditional Chinese medicine (TCM) as an adjunctive therapy in oral cancer management. The study included 80 patients with oral cancer to evaluate the effects of the Tongluo Jiedu prescription on inflammatory stress markers, peripheral blood T-cell subsets, and overall immune function. The results indicated that Tongluo Jiedu substantially enhances immune function and reduces oxidative stress, thereby aiding in patient recovery and potentially minimizing treatment-related complications. This editorial discusses the broader implications of these findings for oral cancer care and emphasizes the importance of integrating TCM principles into modern oncology practices.
Core Tip: The study provides valuable insights into the effectiveness of the Tongluo Jiedu prescription as an adjunctive therapy in oral cancer management. By prospectively evaluating immune function and oxidative stress levels in patients with oral cancer receiving Tongluo Jiedu prescription alongside conventional chemotherapy, the study highlighted the potential of traditional Chinese medicine in enhancing patient outcomes. The findings suggest that the Tongluo Jiedu prescription could be a valuable complementary approach to reduce treatment-related complications and accelerate recovery in oral cancer care.
